Kidney Week

Abstract: SA-PO389

Prognostic Value of Secretoneurin in Patients Treated with Chronic Hemodialysis

Session Information

• Hemodialysis and Frequent Dialysis - 2
  October 26, 2024 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Dialysis

• 801 Dialysis: Hemodialysis and Frequent Dialysis

Authors

• Liboriussen, Caroline H., Aalborg Universitetshospital, Aalborg, Denmark

Caroline H. Liboriussen, MD

• Nygaard, Louis, Aalborg Universitetshospital, Aalborg, Denmark

Louis Nygaard, MD

• Lyngbakken, Magnus N., Akershus Universitetssykehus HF, Lorenskog, Norway

Magnus N. Lyngbakken, MD, PhD

• Jensen, Jens Dam, Aalborg Universitetshospital, Aalborg, Denmark

Jens Dam Jensen, MD, PhD

• Glerup, Rie Io, Aalborg Universitetshospital, Aalborg, Denmark

Rie Io Glerup, MD, PhD

• Omland, Torbjorn, Akershus Universitetssykehus HF, Lorenskog, Norway

Torbjorn Omland, DrMed

• Rosjo, Helge, Akershus Universitetssykehus HF, Lorenskog, Norway

Helge Rosjo, MD, PhD

• Svensson, My, Aalborg Universitetshospital, Aalborg, Denmark

My Svensson, MD, PhD, MPA

Background

Secretoneurin (SN) is a novel biomarker with an upper reference limit (97.5th percentile) of 60 pmol/L in healthy subjects. High SN concentrations are associated with increased risk of mortality in patients with cardiovascular (CV) disease. This study investigated the association between SN and the risk of CV events and all-cause mortality in patients receiving hemodialysis (HD).

Methods

Prospective multicenter cohort study with 5 years of follow-up. Serum SN (pmol/L) was measured at baseline. Primary outcome was CV events; secondary outcomes were all-cause mortality and each component of CV events. The population was divided into tertiles according to SN concentrations (pmol/L): tertile 1 <110.7, tertile 2 from 110.7-143, and tertile 3 >143. The association between SN tertiles and outcomes was analyzed with adjusted Cox regression analysis.

Results

The study included 336 patients on HD. Median SN concentration was 126 (IQR 100-153) pmol/L. During follow-up 60% died and 42% had a CV event. After adjusting for relevant confounders neither SN tertile 2 nor SN tertile 3 were associated with the risk of CV events (HR_tertile2 1.27 (95% CI 0.84-1.93) and HR_tertile3 1.20 (95% CI 0.76-1.90)) or all-cause mortality (HR_tertile2 0.84 (95% CI 0.60-1.18) and HR_tertile3 0.90 (95% CI 0.62-1.31)), when compared to tertile 1 (Fig. 1).

Conclusion

Patients receiving HD have high SN concentrations; however, SN was not associated with CV events or all-cause mortality. High concentrations of SN, possibly explained by both impaired renal clearance and a high prevalence of cardiomyopathy, may limit its prognostic relevance in patients receiving HD.

Fig 1. Association between secretoneurin tertiles and outcomes. *Cardiovascular (CV) events include acute myocardial infarction, unstable angina pectoris, stroke, transient ischemic attack, peripheral arterial disease, and CV mortality.